Trials
5 active
10 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypertriglyceridemia, Hyperlipidemia, Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
- Main trialPhase 3
- “The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.”In the company’s words, NCT07349615 on ClinicalTrials.gov
Other drugs for Hypertriglyceridemia
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- PlozasiranArrowhead · Phase 3
- MN-001MediciNova · Phase 2
- RBD5044Ribotek Biopharmaceuticals (Shandong) Co., Ltd · Phase 2
- SolbinsiranEli Lilly · Phase 2
Coming up4
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Mar 2027 | A Study of SHR-1918 In Participants With Hypertriglyceridemia | |
| Phase 3Recruiting | Oct 2027 | A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | |
| Phase 2/3Recruiting | Jul 2028 | A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors | |
| Phase 2Not yet recruiting | Dec 2025 | Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 2Active, not recruiting | Jun 2027 | Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis | |
| Phase 3Completed | 25 Aug 2025 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 2Completed | 29 Jun 2024 | Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 2Completed | 16 May 2025 | Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | |
| Phase 2Completed | 4 Jul 2025 | Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic | |
| Phase 1Unknown | 11 Dec 2023 | Safety and Tolerability of SHR-1918 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026